Invasive Zygomycosis: Update on Pathogenesis, Clinical Manifestations, and Management

Infectious Disease Clinics of North America

Volumn 20, Issue 3, 2006, Pages 581-607

  Kontoyiannis, Dimitrios P ^a   Lewis, Russell E ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL FEATURE; HUMAN; IMMUNE RESPONSE; LUNG INFECTION; MUCORMYCOSIS; PATHOGENESIS; PROGNOSIS; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION;

ANTIFUNGAL AGENTS; HUMANS; ZYGOMYCOSIS;

EID: 33748519574     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2006.06.003     Document Type: Review

References (103)

1. Larone D.H. Medically important fungi-a guide to identification. 3rd edition (1995), American Society for Microbiology Press, Washington (DC)
2. Spellberg B., Edwards Jr. J., and Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 18 3 (2005) 556-569
3. Chayakulkeeree M., Ghannoum M.A., and Perfect J.R. Zygomycosis: the re-emerging fungal infection. Eur J Clin Microbiol Infect Dis 25 (2006) 28
4. Ibrahim A., Edwards Jr. J.E., and Filler S.G. Zygomycosis (2004), Harcourt Brace, Philadelphia
5. Ribes J.A., Vanover-Sams C.L., and Baker D.J. Zygomycetes in human disease. Clin Microbiol Rev 13 2 (2000) 236-301
6. Roden M.M., Zaoutis T.E., Buchanan W.L., et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41 5 (2005) 634-653
7. Mead J.H., Lupton G.P., Dillavou C.L., et al. Cutaneous Rhizopus infection. Occurrence as a postoperative complication associated with an elasticized adhesive dressing. JAMA 242 3 (1979) 272-274
8. Mitchell S.J., Gray J., Morgan M.E., et al. Nosocomial infection with Rhizopus microsporus in preterm infants: association with wooden tongue depressors. Lancet 348 9025 (1996) 441-443
9. Kontoyiannis D.P., Wessel V.C., Bodey G.P., et al. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 30 6 (2000) 851-856
10. Rees J.R., Pinner R.W., Hajjeh R.A., et al. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis 27 5 (1998) 1138-1147
11. Chamilos G., Luna M., Lewis R.E., et al. Invasive fungal infections in patients with hematological malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Hematologica 91 (2006) 988-991
12. Kontoyiannis D.P., Lionakis M.S., Lewis R.E., et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191 8 (2005) 1350-1360
13. Marr K.A., Carter R.A., Crippa F., et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34 7 (2002) 909-917
14. Pagano L., Girmenia C., Mele L., et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 86 8 (2001) 862-870
15. Pagano L., Ricci P., Tonso A., et al. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. GIMEMA Infection Program (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto). Br J Haematol 99 2 (1997) 331-336
16. Imhof A., Balajee S.A., Fredricks D.N., et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 39 5 (2004) 743-746
17. *M-666]. Washington, DC, October 30-November 2.
18. Siwek G.T., Dodgson K.J., de Magalhaes-Silverman M., et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 39 4 (2004) 584-587
19. Kurukularatne C, Garcia-Diaz J, Kemmerly S, Reed D, et al. Beyond Rhizopus and Mucor: Hurricane Katrina stirs up Synephalastrum in New Orleans. Presented at Focus on Fungal Infections 16. Las Vegas, March 8-10, 2006.
20. Greenberg R.N., Scott L.J., Vaughn H.H., et al. Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Curr Opin Infect Dis 17 6 (2004) 517-525
21. Abzug M.J., Gardner S., Glode M.P., et al. Heliport-associated nosocomial mucormycoses. Infect Control Hosp Epidemiol 13 6 (1992) 325-326
22. Weems Jr. J.J., Davis B.J., Tablan O.C., et al. Construction activity: an independent risk factor for invasive aspergillosis and zygomycosis in patients with hematologic malignancy. Infect Control 8 2 (1987) 71-75
23. Parker C., Kaminski G., and Hill D. Zygomycosis in a tattoo, caused by Saksenaea vasiformis. Australas J Dermatol 27 3 (1986) 107-111
24. Prevoo R.L., Starink T.M., and de Haan P. Primary cutaneous mucormycosis in a healthy young girl. Report of a case caused by Mucor hiemalis Wehmer. J Am Acad Dermatol 24 5 Pt 2 (1991) 882-885
25. Bouchara J.P., Oumeziane N.A., Lissitzky J.C., et al. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol 70 1 (1996) 76-83
26. Ibrahim A.S., Spellberg B., Avanessian V., et al. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 73 2 (2005) 778-783
27. Partida-Martinez L.P., and Hertweck C. Pathogenic fungus harbours endosymbiotic bacteria for toxin production. Nature 437 7060 (2005) 884-888
28. Waldorf A.R., and Diamond R.D. Neutrophil chemotactic responses induced by fresh and swollen Rhizopus oryzae spores and Aspergillus fumigatus conidia. Infect Immun 48 2 (1985) 458-463
29. Waldorf A.R., Levitz S.M., and Diamond R.D. In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus. J Infect Dis 150 5 (1984) 752-760
30. Waldorf A.R., Ruderman N., and Diamond R.D. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 74 1 (1984) 150-160
31. Lionakis M.S., and Kontoyiannis D.P. Glucocorticoids and invasive fungal infections. Lancet 362 9398 (2003) 1828-1838
32. Chinn R.Y., and Diamond R.D. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 38 3 (1982) 1123-1129
33. Richardson M., and Warnock D. Mucormycosis (2003), Blackwell, Oxford (UK)
34. Crichton R. Iron and infection. 2nd edition (2001), Wiley and Sons, London
35. Gaziev D., Baronciani D., Galimberti M., et al. Mucormycosis after bone marrow transplantation: report of four cases in thalassemia and review of the literature. Bone Marrow Transplant 17 3 (1996) 409-414
36. Sands J.M., Macher A.M., Ley T.J., et al. Disseminated infection caused by Cunninghamella bertholletiae in a patient with beta-thalassemia. Case report and review of the literature. Ann Intern Med 102 1 (1985) 59-63
37. Howard D.H. Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev 12 3 (1999) 394-404
38. Artis W.M., Fountain J.A., Delcher H.K., et al. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 31 12 (1982) 1109-1114
39. Artis W.M., Patrusky E., Rastinejad F., et al. Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: alternative to simple iron deprivation. Infect Immun 41 3 (1983) 1269-1278
40. Boelaert J.R., de Locht M., and Schneider Y.J. The effect of deferoxamine on different zygomycetes. J Infect Dis 169 1 (1994) 231-232
41. Boelaert J.R., de Locht M., Van Cutsem J., et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 91 5 (1993) 1979-1986
42. Boelaert J.R., Van Cutsem J., de Locht M., et al. Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect. Kidney Int 45 3 (1994) 667-671
43. de Locht M., Boelaert J.R., and Schneider Y.J. Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 47 10 (1994) 1843-1850
44. Mencacci A., Cenci E., Boelaert J.R., et al. Iron overload alters innate and T helper cell responses to Candida albicans in mice. J Infect Dis 175 6 (1997) 1467-1476
45. Verpooten G.A., D'Haese P.C., Boelaert J.R., et al. Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. Nephrol Dial Transplant 7 9 (1992) 931-938
46. Bhansali A., Bhadada S., Sharma A., et al. Presentation and outcome of rhino-orbital-cerebral mucormycosis in patients with diabetes. Postgrad Med J 80 949 (2004) 670-674
47. Yohai R.A., Bullock J.D., Aziz A.A., et al. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 39 1 (1994) 3-22
48. Frater J.L., Hall G.S., and Procop G.W. Histologic features of zygomycosis: emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med 125 3 (2001) 375-378
49. Fatterpekar G., Mukherji S., Arbealez A., et al. Fungal diseases of the paranasal sinuses. Semin Ultrasound CT MR 20 6 (1999) 391-401
50. Chamilos G., Marom E.M., Lewis R.E., et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis 41 1 (2005) 60-66
51. Lee F.Y., Mossad S.B., and Adal K.A. Pulmonary mucormycosis: the last 30 years. Arch Intern Med 159 12 (1999) 1301-1309
52. McAdams H.P., Rosado de Christenson M., Strollo D.C., et al. Pulmonary mucormycosis: radiologic findings in 32 cases. AJR Am J Roentgenol 168 6 (1997) 1541-1548
53. Tedder M., Spratt J.A., Anstadt M.P., et al. Pulmonary mucormycosis: results of medical and surgical therapy. Ann Thorac Surg 57 4 (1994) 1044-1050
54. Goldstein M.F., Dvorin D.J., Dunsky E.H., et al. Allergic Rhizomucor sinusitis. J Allergy Clin Immunol 90 3 Pt 1 (1992) 394-404
55. Dykewicz M.S., Laufer P., Patterson R., et al. Woodman's disease: hypersensitivity pneumonitis from cutting live trees. J Allergy Clin Immunol 81 2 (1988) 455-460
56. Andresen D., Donaldson A., Choo L., et al. Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka. Lancet 365 9462 (2005) 876-878
57. Patino J.F., Castro D., Valencia A., et al. Necrotizing soft tissue lesions after a volcanic cataclysm. World J Surg 15 2 (1991) 240-247
58. Bittencourt A.L., Ayala M.A., and Ramos E.A. A new form of abdominal zygomycosis different from mucormycosis: report of two cases and review of the literature. Am J Trop Med Hyg 28 3 (1979) 564-569
59. Oliver M.R., Van Voorhis W.C., Boeckh M., et al. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis 22 3 (1996) 521-524
60. Park Y.S., Lee J.D., Kim T.H., et al. Gastric mucormycosis. Gastrointest Endosc 56 6 (2002) 904-905
61. Branton M.H., Johnson S.C., Brooke J.D., et al. Peritonitis due to Rhizopus in a patient undergoing continuous ambulatory peritoneal dialysis. Rev Infect Dis 13 1 (1991) 19-21
62. Polo J.R., Luno J., Menarguez C., et al. Peritoneal mucormycosis in a patient receiving continuous ambulatory peritoneal dialysis. Am J Kidney Dis 13 3 (1989) 237-239
63. Nakamura M., Weil Jr. W.B., and Kaufman D.B. Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine. Pediatr Nephrol 3 1 (1989) 80-82
64. Schwartz J.R., Nagle M.G., Elkins R.C., et al. Mucormycosis of the trachea: an unusual cause of acute upper airway obstruction. Chest 81 5 (1982) 653-654
65. Connor B.A., Anderson R.J., and Smith J.W. Mucor mediastinitis. Chest 75 4 (1979) 525-526
66. Marwaha R.K., Banerjee A.K., Thapa B.R., et al. Mediastinal zygomycosis. Postgrad Med J 61 718 (1985) 733-735
67. Lussier N., Laverdiere M., Weiss K., et al. Primary renal mucormycosis. Urology 52 5 (1998) 900-903
68. Echols R.M., Selinger D.S., Hallowell C., et al. Rhizopus osteomyelitis. A case report and review. Am J Med 66 1 (1979) 141-145
69. Mishra B., Mandal A., and Kumar N. Mycotic prosthetic-valve endocarditis. J Hosp Infect 20 2 (1992) 122-125
70. Roy T.M., Anderson K.C., and Farrow J.R. Cardiac mucormycosis complicating diabetes mellitus. J Diabetes Complications 4 3 (1990) 132-135
71. Sanchez-Recalde A., Merino J.L., Dominguez F., et al. Successful treatment of prosthetic aortic valve mucormycosis. Chest 116 6 (1999) 1818-1820
72. Zhang R., Zhang J.W., and Szerlip H.M. Endocarditis and hemorrhagic stroke caused by Cunninghamella bertholletiae infection after kidney transplantation. Am J Kidney Dis 40 4 (2002) 842-846
73. Bosken C.H., Szporn A.H., and Kleinerman J. Superior vena cava syndrome due to mucormycosis in a patient with lymphoma. Mt Sinai J Med 54 6 (1987) 508-511
74. Tierney M.R., and Baker A.S. Infections of the head and neck in diabetes mellitus. Infect Dis Clin North Am 9 1 (1995) 195-216
75. Chandler F., Kaplan W., and Ajello L. A colour atlas and textbook of the histopathology of mycotic diseases (1980), Wofle Medical Publications, Ltd., London
76. Bialek R., Konrad F., Kern J., et al. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J Clin Pathol 58 11 (2005) 1180-1184
77. Kobayashi M., Togitani K., Machida H., et al. Molecular polymerase chain reaction diagnosis of pulmonary mucormycosis caused by Cunninghamella bertholletiae. Respirology 9 3 (2004) 397-401
78. Rickerts V., Just-Nubling G., Konrad F., et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis 25 1 (2006) 8-13
79. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard NCCLS document M38-A (2002), National Committee for Clinical Laboratory Standards, Wayne, PA
80. Dannaoui E., Meletiadis J., Mouton J.W., et al. In vitro susceptibilities of zygomycetes to conventional and new antifungals. J Antimicrob Chemother 51 1 (2003) 45-52
81. Ullmann A.J., Cornely O.A., Burchardt A., et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 50 2 (2006) 658-666
82. Greenberg R.N., Mullane K., van Burik J.A., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 50 1 (2006) 126-133
83. Courtney R., Pai S., Laughlin M., Lim J., et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 47 9 (2003) 2788-2795
84. Spellberg B., Fu Y., Edwards Jr. J.E., et al. Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 49 2 (2005) 830-832
85. Dannaoui E., Afeltra J., Meis J.F., et al. In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents. Antimicrob Agents Chemother 46 8 (2002) 2708-2711
86. Ibrahim A.S., Bowman J.C., Avanessian V., et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 49 2 (2005) 721-727
87. van Burik J.A., Hare R.S., Solomon H.F., et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42 7 (2006) e61-e65
88. Perfect J.R. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 40 Suppl 6 (2005) S401-S408
89. Gleissner B., Schilling A., Anagnostopolous I., et al. Improved outcome of zygomycosis in patients with hematological diseases?. Leuk Lymphoma 45 7 (2004) 1351-1360
90. Lewis R.E., and Wiederhold N.P. The solubility ceiling: a rationale for continuous infusion amphotericin B therapy?. Clin Infect Dis 37 6 (2003) 871-872
91. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B (L-AMB) as initial therapy for invasive filamentous fungal infections (IFFI): a randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Presented at the 47th annual meeting of the American Society for Hematology. Atlanta, December 10-13 2005.
92. Dannaoui E., Mouton J.W., Meis J.F., et al. Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis. Antimicrob Agents Chemother 46 6 (2002) 1953-1959
93. Torres H.A., Hachem R.Y., Chemaly R.F., et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 5 12 (2005) 775-785
94. Paterson P.J., Seaton S., Prentice H.G., et al. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 52 5 (2003) 873-876
95. Shafer M.R. Use of hyperbaric oxygen as adjunct therapy to surgical debridement of complicated wounds. Semin Perioper Nurs 2 4 (1993) 256-262
96. Price J.C., and Stevens D.L. Hyperbaric oxygen in the treatment of rhinocerebral mucormycosis. Laryngoscope 90 5 Pt 1 (1980) 737-747
97. Kajs-Wyllie M. Hyperbaric oxygen therapy for rhinocerebral fungal infection. J Neurosci Nurs 27 3 (1995) 174-181
98. Ferguson B.J., Mitchell T.G., Moon R., et al. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 10 3 (1988) 551-559
99. Couch L., Theilen F., and Mader J.T. Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy. Arch Otolaryngol Head Neck Surg 114 7 (1988) 791-794
100. Barratt D.M., Van Meter K., Asmar P., et al. Hyperbaric oxygen as an adjunct in zygomycosis: randomized controlled trial in a murine model. Antimicrob Agents Chemother 45 12 (2001) 3601-3602
101. Gil-Lamaignere C., Simitsopoulou M., Roilides E., et al. Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes. J Infect Dis 191 7 (2005) 1180-1187
102. Abzug M.J., and Walsh T.J. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J 23 8 (2004) 769-773
103. Slavin M.A., Kannan K., Buchanan M.R., et al. Successful allogeneic stem cell transplant after invasive pulmonary zygomycosis. Leuk Lymphoma 43 2 (2002) 437-439